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Abstract
Detecting and characterizing of anti-drug antibodies (ADA) against a protein therapeutic
are crucially important to monitor the unwanted immune response. Usually a multi-tiered
approach that initially rapidly screens for positive samples that are subsequently confirmed
in a separate assay is employed for testing of patient samples for ADA activity. In this
manuscript we evaluate the ability of different methods used to classify subject with screen-
ing and competition based confirmatory assays. We find that for the overall performance of
the multi-stage process the method used for confirmation is most important where a t-test
is best when differences are moderate to large. Moreover we find that, when differences
between positive and negative samples are not sufficiently large, using a competition based
confirmation step does yield poor classification of positive samples.
Keywords: Anti-drug antibody, confirmatory, cut point, immunoassay, immunogenicity,
screening, specificity
1. Introduction1
Detecting and characterizing of anti-drug antibodies (ADA) against a protein ther-2
apeutic are crucially important to monitor the unwanted immune response. Usually a3
multi-tiered approach that initially rapidly screens for positive samples that are subse-4
quently confirmed in a separate assay is employed for testing of patient samples for ADA5
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presence. Several regulatory guidelines [1, 2, 3] and white papers [4, 5, 6] describe the6
testing strategies, assay formats, validation requirements and performance expectations7
for such assays have been published.8
9
In order to use either screening or confirmatory assays, establishing cut points that10
are used to classify into negative and positive samples are paramount. An upper negative11
limit of 95% for the screening cut point is recommended [1, 2, 4, 6], resulting in a 5%12
false-positive rate. The subsequent confirmation assay used here aims to eliminate false13
positive samples based on competition assays. These competition assays are a tool to iden-14
tify possible signal contribution from unspecific antibody binding and additionally analyze15
all samples using a study-drug inhibited assay. This assay is basically set up identically16
to the uninhibited assay with the exception that all samples are pre-incubated with ex-17
cess amount of free specific protein antigen (“antigen competition”). Specific antibodies18
directed against the particular antigen are bound in the form of immune complexes in the19
liquid phase and subsequently removed during washing steps. Hence, the specificity of20
antibodies detected with the uninhibited assay can be confirmed by a reduction of signal21
in the inhibited assay. Recently various methods for finding cut points for screening assays22
[7, 8] and confirmatory assays [9] have been evaluated.23
24
One of the unexpected and striking findings when evaluating the performance of confir-25
matory assays [9] was that extremely large differences between uninhibited and inhibited26
samples are necessary to separate positive from negative samples. This surprising finding27
led us to investigate the capability of the multi-tier approach to separate positive and neg-28
ative samples. In this manuscript we will evaluate the ability of the multi-tier approach29
for classifying samples in both simulations and real data evaluations.30
2. Classifying samples31
Previously a large number of different approaches for classifying screening [e.g. 6, 7] and32
confirmatory assays [e.g. 9] have been described. In this evaluation we consider 7 methods33
to be used in screening assays and three approaches for confirmatory assays yielding 21 dif-34
ferent combination of approaches. We have attempted to be as comprehensive as possible35
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in the methods investigated, yet the sheer number of approaches currently in the literature36
disallowed a full evaluation. The most notable ideas that have not been considered here37
is the simplified decision tree in [10] and the fixed percent inhibition method [6, 9]. The38
former was excluded as initial evaluations revealed an undistinguishable performance to39
the decision tree in [6] while the latters subjective choice of what percentage ought to be40
used was prohibitive.41
42
In this section we will describe the different methods for classifying samples. The43
principle idea of each approach for confirmatory assays is to determine if the change in assay44
signal with and without pre-incubation of a sample with high amounts of the therapeutic45
drug is large enough to be a relevant indicator to distinguish between true positive and false46
positive samples. We will therefore consider the situation where measurements without47
pre-incubation for each sample are available (the screening data) and that measurements48
with and without preincubation are available for confirmation. For the latter we also49
assume pre-incubation is successful and truly leads to inhibition. Moreover, we assume that50
multiple runs (analyses) per sample are undertaken and that measurements are corrected51
for run noise. As in [9] we will use an average of the runs per sample (e.g. mean per52
subject across runs) to utilize multiple runs recognizing that more involved methods may53
be necessary depending on the underlying experimental design [e.g. 11]. Measurements with54
pre-incubation of the therapeutic drug will be referred to as “inhibited measurements” and55
without incubation as “uninhibited measurements”.56
2.1. Methods for classification: Screening assays57
Method S1: 95th percentile58
59
The cut point is found as the 95th percentile of the uninhibited observations.60
61
Method S2: Parametric method62
63
The cut-off value is calculated as X¯+z0.95*SD, where X¯ and SD are the mean and stan-64
dard deviation of the uninhibited measurements respectively and z0.95 is the 95% percentile65
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of the standard normal distribution (approximately 1.645).66
67
Method S3: Robust parametric method68
69
The cut point is found as X˜+z0.95*1.483*MAD, where X˜ and MAD are the median70
and median absolute deviation of the uninhibited measurements respectively and z0.95 is71
the 95% percentile of the standard normal distribution as before.72
73
Method S4: Decision tree74
75
The following decision tree, as described in [6], is used to find the cut-point.76
1. Perform a Shapiro-Wilks test [12] to assess normality of the uninhibited data. If the77
p-value is < 0.05 the data are log-transformated.78
2. Calculate the 25% and 75% percentile, X0.25 and X0.75, of the (transformed) data.79
Eliminate all data points outside the interval [X0.25 - 1.5*(X0.75 - X0.25); X0.75 +80
1.5*(X0.75 - X0.25)]. This corresponds to eliminating data that are classed as outliers81
in a box-whisker plot [e.g. 13].82
3. Perform the Shapiro-Wilks test [12] to assess normality using the remaining data. If83
the p-value is < 0.05, use the 95% percentile to calculate the intermediate cut point,84
otherwise the parametric method is used.85
4. If data were log-transformed take the anti-logarithm of the intermediate cut point as86
final cut point otherwise the intermediate cut point is the final cut point.87
Note, that in general it is not recommended to test every data set for normality and use88
the result to decide between parametric and nonparametric statistical tests [e.g. 14, 15].89
This procedure has, however, been proposed as a compromise between statistical rigour90
and practicality.91
92
Method S5: Mixture model93
94
This method, which has been proposed in [7], aims to identify if samples are negative95
or positive and then only uses the negative samples to find the cut point. The approach96
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uses (regression) mixture models [e.g. 16, 17, 18] that allow different populations (in this97
application postive and negative subjects) to follow different probability distributions.98
99
The approach is to firstly identify, using the Bayesian Information Criterion (BIC)100
if there is more than one population in the screening data. If there is more than one101
population, then only samples belonging to the larger population, which is assumed to102
be corresponding to negative samples, will be used for cut point determination while all103
screening data are used otherwise. The cut point is then found as the 95th percentile of104
the observations. A formal description and details on the specific implementation of this105
method are provided in the supplementary materials.106
107
Method S6: Prediction intervals108
109
This approach is advocated in [8] and is based on obtaining intervals for future ob-110
servations based on m historical observations. In particular the cut-point is found as111
X¯+t0.95,m−1*SD*
√
1 + 1/m, where X¯ and SD are the mean and standard deviation of112
the uninhibited measurements respectively and t0.95,m−1 is the 95% percentile of a t-113
distribution with m− 1 degrees of freedom.114
115
Method S7: Experimental approach116
117
The experimental approach, which utilizes screening and confirmatory assay data to-118
gether obtains the cut point through the following steps:119
1. Find a preliminary cut point for the inhibited samples based on the 95% percentile120
method;121
2. Use the preliminary cut point to classify uninhibited values into positive and negative122
samples;123
3. Create a new dataset containing all screening samples below the preliminary cut point124
and all screening samples larger than the preliminary cut-off value provided that the125
confirmatory value is larger than the screening value. The second set of samples is126
included as such observations correspond to an nonspecific signal (false positives);127
5









4. Use the 95% percentile method with the new dataset to get the final cut-point.128
2.2. Methods for classification: Confirmatory assays129
Method C1: Parametric difference130
131
Find the difference between uninhibited and inhibited measurement for each sample132
D = uninhibited measurement− inhibited measurement.
The cut point is found as cD = D¯+ z0.999 ∗σD where D¯ is the average difference across133
all samples, σD is the corresponding standard deviation and z0.999 is the 99.9% percentile134
of the standard normal distribution (approximately 3.09).135
136
Method C2: Parametric % inhibition137
138
For each sample find the percent change in inhibition as139





The inhibition based cut point is found as cI = I¯ + z0.999 ∗ σI where I¯ is the average140
percent change in inhibition across all samples, σI is the corresponding standard deviation141




Perform a one-sided 2-sample t-test of all runs of the log-transformed study drug inhib-146
ited values against the log-transformed uninhibited values for each sample. If the resulting147
p-value is less than 0.01 the sample is classed positive.148
3. Simulation of multi-tiered approach149
We begin by considering simulations of the 2-stage classification approach in this sec-150
tion. This has the advantage that it is exactly known whether a specific value is positive151
or negative, allowing for an informed comparison of the different approaches. For a more152
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in-depth evaluation we will consider samples to be either truly positive, false positive or153
truly negative. For simulation, true positive samples show high measurements when un-154
inhibited, but low values under inhibition, false positives have high measurements when155
uninhibited and inhibited while true negative samples have low measurements under both156
conditions.157
158
We will generate data for this evaluation in two parts. In the first part, data that159
are used to determine the cut-points are simulated from a population that only contains160
negative samples. Both inhibited and uninhibited samples will be generated and we will161
use 160 samples in the first part of the evaluation as previous work [7, 9] suggests limited162
impact of sample size. The second part of the data are used to evaluate the performance163
of the classification methods and cut-points found based on the first set of data. The data164
are generated to contain 85% true negative samples, 10% of the data are truly positive165
and 5% are false positive samples. To ensure accurate estimation of the classification rates166
we will simulate 1,000 samples and estimate the classification rates based on these data.167
Both normal and log-normally distributions are evaluated and 1,000 simulation runs are168
performed. Three runs will be used for establishing cut points and evaluating classification.169
Table 1 in the supplementary materials shows the exact parameters used to generate the170
data. Note that, while only a limited set of evaluations are presented here, many more171
simulations have been run. As the conclusions from these were qualitatively the same as172
the once presented, we have omitted them here for brevity.173
174
To evaluate the performance of the classifications we will look at the proportion of175
correctly classified true positive, true negative and false positive samples averaged over176
1,000 simulation runs. We begin, however, by considering the number of samples that177
are selected for confirmation as this number has direct implications for the practicability178
of the classification method. Note, that we expect around 200 observations to be classed179
as positive at this stage, as 10% of the 1000 observations are truly positive, 5% are false180
positive and the cut-points are found so that 5% error in classing negative samples are al-181
lowed. Figure 1 shows the distribution of the number of samples that are classed as positive182
based on the screening data for the seven different methods. The first notable observation183
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is that the experimental approach classes almost twice as many observations as positive184
than the other approaches. Consequently the risk of missing a positive signal at this stage185
is lower for that approach while at the same time the risk of including large numbers of186
truly negative samples in the confirmation step is also increased. Secondly, the difference in187
number of samples classed positive is (on average) quite similar for all the other approaches188
although more variability is observed in the mixture approach. It is however notable that189
for the situation with a small difference between positive and negative samples, only about190
100 samples are considered positive and hence a high risk of false negatives exists, while191
the larger differences between positive and negative samples yield numbers quite close to192
the expected 200 samples. Additional evaluations (not shown) suggest, that the number of193
positive samples is very stable once the difference between positive and negative samples194
is sufficiently large. For normally distributed data, for example, this difference needs to be195
around 2.5 standard deviations.196
197
∼∼ Figure 1 about here ∼∼198
Next we evaluate the ability of the various approaches to classify correctly. The objec-199
tive of this evaluation is two-fold. Firstly we wish to see how well commonly used clas-200
sification approaches for immunogenicity assays work in realistic situations and secondly201
determine which approach (that is which combination of methods for cutpoint calculation202
for screening assay and confirmation assay) is best. We begin by focusing on the overall203
classification rates, when the robust parametric approach, which in [7] is found to be one204
of the best performing methods, is used for the screening assays. Figure 2 shows a clear205
separation between the methods for classification for confirmatory assays investigated. The206
% inhibition methods performs far worse than the other two approaches in classifying true207
positive samples, when the robust parametric method is used for the screening assays. The208
difference between the parametric difference and the t-test is more nuanced, however. The209
t-test performs best classifying true positive samples - only for large difference between210
positive and negative samples the parametric difference is marginally better. When look-211
ing at the classification performance of the different approaches of samples that are truly212
negative, the parametric difference is slightly better, although the t-test also results in a213
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large proportion of correct classifications. This small difference is expected, however, as214
the number of correct classifications is dominated by the method used for the screening215
data. The parametric difference is clearly superior to the t-test in classifying false positives216
which only achieves about 80% correct classifications. It also shows a peculiar dip in the217
proportion of correct classifications for medium differences between positive and negative218
samples.219
∼∼ Figure 2 about here ∼∼220
The evaluation shown in Figure 2 focuses on the situation, where the robust paramet-221
ric difference is used for the screening assays. Although the classification rates do differ222
slightly, when using other methods during the screening phase, the relative patterns de-223
scribed above are the same. It is notable, that the difference between positive and negative224
samples needs to be quite large in order to see good classification of true positive samples,225
while the classification of true negatives and false positives is much less effected by that226
difference. To investigate the combination of methods further, we now look at the different227
methods for classifying screening assay data. Figure 3 show the overall classification rates228
for each screening classification method when the confirmation uses the t-test. The para-229
metric and the robust parametric method result in the best classification rates for truly230
positive samples while all methods appear to give good classification of negative samples.231
The mixture model approach and the prediction interval are best in determining false pos-232
itive samples. Overall, the percentile approach and the parametric methods appear to233
provide best results. As the difference between methods is most pronounced for small dif-234
ferences between the positive and negative samples, the graph displays a 1 and 1.2 standard235
deviation difference for normal and log-normal data, respectively. The overall patterns are236
the same as this difference increases, however. It is worth noting that the methods become237
almost indistinguishable for differences that classify an adequate proportion of subjects238
correctly.239
∼∼ Figure 3 about here ∼∼240
The evaluations so far clearly indicate that the method used for screening has little241
bearing on the overall ability to classify correctly when using a 2-tier approach while242
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the method used for confirmation is of high importance. A simple t-test performs best243
in classifying true positive samples but does not do so well in classifying false positives.244
In contrast a simple difference approach has good classification for false positives, yet245
only results in adequate classification rates if the difference between positive and negative246
samples are very large. This raises the immediate question whether a confirmatory assay247
should be used at all. To investigate this further we contrast the classification rates after248
screening only and after screening and confirmation. The robust parametric method is249
used for the screening assays while the parametric difference is used for confirmation.250
∼∼ Figure 4 about here ∼∼251
Figure 4 shows that using a confirmatory assay has an notable effect on the ability to252
classify positive sample correctly for small to moderate differences between positive and253
negative samples. At the same time the confirmatory assays do result in a much improved254
false positive rate. When using the % inhibition approach the results are even worse in255
terms of classifying positive samples. The results for the t-test are closer to the ones ob-256
tained by using screening alone but result in much worse classification for false positive257
samples (see Figure 2).258
259
4. Differences in methods for a specific example260
The previous evaluations were based on simulated data but suggest that it may not be261
beneficial for classifying ADA positive and ADA negative samples to use a confirmation262
assay. In this section we consider a real dataset (illustrated in Figure 5 and full dataset263
provided in Table 2 of the supplementary materials) to highlight where the different ap-264
proaches lead to distinct conclusions.265
266
The data set was generated by means of a direct-binding enzyme-linked immunosorbent267
assay (ELISA). The ELISA was designed to detect total Ig antibodies (i.e. isotypes IgG,268
IgM and IgA) specifically directed against a particular protein antigen. Plasma samples269
from 160 clinically healthy plasma donors were analyzed, each using three runs with and270
without inhibition. For the uninhibited runs, micro-titer plates (Nunc/ThermoScientific,271
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Denmark) were coated with the particular protein antigen. Human plasma samples from272
healthy plasma donors (Baxter AG, Austria) were incubated on the plate at a dilution of273
1:20. Antibodies directed against the antigen that were present in the samples bound to the274
antigen. After several washing steps, the antigen-antibody complexes was detected using a275
horseradish peroxidase (HRP)-coupled secondary antibody (goat anti-human Ig antibody;276
AbD Serotec, Germany). The amount of bound secondary antibody was measured by an277
HRP enzyme-dependent color-change reaction using TMB (3,3’,5,5’- tetramethylbenzidine278
solution, AbD Serotec, Germany) as substrate. The color reaction is directly proportional279
to the amount of bound antibodies. The micro-titer plates were subsequently read with280
a plate photometer (ELISA reader Synergy HT; Bio-Tek, USA) in a dual mode at 450nm281
measuring wavelength and 630nm reference wavelength. The dual mode allows the elimi-282
nation of measurement errors due to scratches or dirt on the micro-titer plates. Delta-OD283
(=optical density at 450nm minus optical density at 630nm) corrected by the blank value284
is taken into account as optical density (OD) for evaluation. Each sample was analyzed in285
independent triplicates by two different analysts on different days.286
287
As a tool to identify possible signal contribution from unspecific antibody binding,288
all samples were additionally analyzed using a study-drug inhibited assay (i.e. confirma-289
tory assay). This assay is basically set up identically to the uninhibited assay with the290
exception that all samples are pre-incubated with excess amount of free specific protein291
antigen (antigen competition). Specific antibodies directed against the particular antigen292
are bound in the form of immune complexes in the liquid phase and subsequently removed293
during washing steps. Hence, the specificity of antibodies detected with the uninhibited294
assay can be confirmed by a reduction of OD signal in the inhibited assay.295
296
Close examination of the data shows that a large variability both between subjects and297
between runs exists in this dataset. Similarly one can observe that the responses increase298
after the addition of the antigen for a number of subjects. This is somewhat surprising as299
it is not consistent with the inhibition model and suggests some other confounding factor.300
In such a situation a more advanced modeling approach that accounts for this confounding301
factor may be called for. For the purpose of illustration, however, we will keep with the302
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basic approaches and illustrate the difference in final classification resulting from different303
combinations of methods.304
∼∼ Figure 5 about here ∼∼305
Figure 6 shows the number of samples that are classed as positive for the different stages306
and methods. It can be seen that the different methods for screening classify between 8307
and 19 observations as positive. Looking at the methods for confirmation within each of308
the screening results it is firstly notable that the inhibition based method classes the most309
samples as positive while the difference based method does not class any as positive. More310
interestingly, however, is the fact that, despite substantially different numbers of samples311
being classed possitive during screening, the confirmation step does yield very consistent312
results. The t-test and the difference based method class exactly one and none sample,313
respectively, as positive, irrespective of the screening method used. This underlines once314
more how large the impact of the confirmation step is in comparison to the screening step.315
∼∼ Figure 6 about here ∼∼316
5. Discussion317
In this paper we have evaluated the ability of the multi-tier approach to classify positive318
and negative samples. We find that, irrespective of the specific methods used for deter-319
mining cutpoints for screening and competition assay the approach is able to correctly320
identify truly negative samples as such. Similarly there is high confidence in the correct321
classification of false positive samples. Unfortunately, however, we also find that in gen-322
eral the two-tier approach only identifies positive samples correctly if very large differences323
between positive and negative samples are present. For small differences between positive324
and negative samples positive samples are frequently misclassified. We also find that this325
performance at small differences between inhibited and uninhibited samples is due to a326
lack of sensitivity of the methods of classification for the competition based confirmatory327
assay used in this study. As a consequence, samples with a low signal in the screening328
assay should not be applied to the competition based confirmatory assay because of the329
low confidence of a correct true positive evaluation. Instead, a lower limit for confirmed330
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positive samples should be introduced in addition to the lower limit of detection of any331
antibody in the screening assay [20]. For moderate and small differences using the com-332
petition based confirmatory approach decreases the number of correctly classified positive333
samples drastically.334
335
In our evaluation we have focused on simple methods for classification (a summary of336
the preformance for all combinations of methods is given in Table 3 of the supplementary337
materials) and have not considered more complex methods such as [11]. We have done so338
as the simulated conditions we have considered meant that these simple approaches were339
appropriate. It is clear, however, that more complex real life settings and experimental340
designs will require more complex methods for analysis. Similarly we have focused on sce-341
narios that did not provide any particular additional challenges such as positive samples342
when establishing the screening cut point. It is clear that the findings still have general343
applicability even if more challenging scenarios are considered.344
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Figure 1: Boxplots of the number of samples exceeding the screening cut-point for the different methods.
Panels (a) and (b) display normally distributed data with 1 and 5 standard deviation difference between
positive and negative samples, respectively. Panels (c) and (d) display log-normally distributed data with
1.2 and 4 standard deviations difference between positive and negative samples, respectively.
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Figure 2: Classification rates across the two stages when the robust parametrics method is used for the
screening assays and different approaches are utilized for the confirmation. A range of differences between
positive and negative samples is investigated.
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Figure 3: Classification rates across the two stages when the t-test is used for the confirmatory assays and
different approaches are utilized for the screening assays. A difference of 1 and 1.2 standard deviations
between positive and negative samples for normal and log-normal data, respectively are used.
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Figure 4: Classification rates when the robust parametric method is used for screening and a parametric
difference is used for the confirmatory assays. A range of differences between positive and negative samples
is investigated.
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ptFigure 5: Histogram of the average screening and competition values per subject.
21









Figure 6: Histogram of number of samples classified as positive after screening (big boxes) and after
confirmation for the different methods.
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Table 1: Parameters used to generate data for simulations. Between run correlation was 0.7 and correlation
between uninhibited and inhibited samples 0.3.
Uninhibited samples Inhibited samples prop prop
Distribution Stage µn µtp = µfp µn µtp µfp σ tp fp
Normal
1 0.3 NA 0.2 NA NA 0.2 0.00 0.00
2 0.3 0.5, 0.6, . . . 2.0 0.2 0.2 0.4, 0.5, . . . 1.9 0.2 0.10 0.05
Log-Normal
1 0.3 NA 0.2 NA NA 0.2 0.00 0.00
2 0.3 0.5, 0.6, . . . 2.0 0.2 0.2 0.4, 0.5, . . . 1.9 0.2 0.10 0.05
µ is mean and σ is standard deviation parameters of distribution. n. . . negative, tp . . . true positive, fp . . . false positive,
prop tp . . . proportion of truly positive samples per stage, prop fp . . . proportion of false positive samples per stage
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Table 2: Measurements with and with-out study drug inhibition of 160 healthy volunteers with 3 runs each used in the example
provided.
uninhibited samples inhibited samples uninhibited samples inhibited samples
# run 1 run 2 run 3 run 1 run 2 run 3 # run 1 run 2 run 3 run 1 run 2 run 3
1 0.284 0.212 0.200 0.310 0.270 0.278 81 0.132 0.131 0.183 0.188 0.246 0.208
2 0.215 0.302 0.149 0.225 0.318 0.278 82 0.162 0.186 0.202 0.239 0.308 0.363
3 0.085 0.138 0.094 0.103 0.137 0.114 83 0.119 0.127 0.151 0.194 0.219 0.241
4 0.161 0.218 0.135 0.153 0.243 0.154 84 0.080 0.092 0.093 0.133 0.180 0.179
5 0.219 0.290 0.185 0.276 0.334 0.270 85 0.103 0.119 0.126 0.116 0.160 0.184
6 0.353 0.463 0.205 0.244 0.393 0.279 86 0.127 0.150 0.137 0.187 0.231 0.223
7 0.185 0.243 0.158 0.211 0.321 0.311 87 0.136 0.113 0.151 0.149 0.140 0.163
8 0.155 0.309 0.111 0.206 0.341 0.142 88 0.090 0.126 0.115 0.164 0.245 0.234
9 0.093 0.089 0.097 0.217 0.192 0.145 89 0.232 0.460 0.261 0.259 0.620 0.317
10 0.079 0.152 0.084 0.133 0.178 0.165 90 0.096 0.122 0.143 0.110 0.193 0.137
11 0.166 0.245 0.127 0.153 0.222 0.247 91 0.220 0.245 0.278 0.296 0.275 0.341
12 0.062 0.118 0.065 0.110 0.160 0.161 92 0.206 0.268 0.286 0.229 0.261 0.350
13 0.148 0.210 0.113 0.205 0.186 0.178 93 0.120 0.122 0.143 0.224 0.290 0.247
14 0.137 0.161 0.091 0.176 0.177 0.175 94 0.421 0.566 0.508 0.444 0.534 0.414
15 0.165 0.223 0.131 0.209 0.251 0.179 95 0.100 0.123 0.128 0.188 0.228 0.194
16 0.245 0.551 0.133 0.345 0.786 0.136 96 0.178 0.129 0.165 0.212 0.192 0.179
17 0.164 0.156 0.118 0.178 0.198 0.114 97 0.110 0.160 0.146 0.163 0.308 0.216
18 0.207 0.387 0.218 0.207 0.273 0.277 98 0.093 0.135 0.133 0.151 0.224 0.259
19 0.147 0.257 0.153 0.222 0.309 0.247 99 0.233 0.313 0.341 0.277 0.365 0.448
20 0.151 0.274 0.133 0.165 0.209 0.166 100 0.077 0.105 0.117 0.175 0.193 0.199
21 0.091 0.163 0.080 0.172 0.286 0.192 101 0.541 0.600 0.497 0.258 0.333 0.354
22 0.075 0.178 0.069 0.101 0.227 0.114 102 0.220 0.262 0.200 0.274 0.309 0.278
23 0.143 0.216 0.110 0.227 0.298 0.159 103 0.177 0.225 0.265 0.261 0.325 0.504
24 0.101 0.352 0.077 0.218 0.519 0.149 104 0.101 0.157 0.087 0.146 0.219 0.160
25 0.092 0.091 0.085 0.176 0.162 0.129 105 0.196 0.259 0.260 0.196 0.319 0.263
26 0.075 0.100 0.121 0.157 0.155 0.159 106 0.115 0.169 0.183 0.179 0.231 0.227
27 0.057 0.082 0.062 0.130 0.179 0.137 107 0.268 0.415 0.475 0.279 0.391 0.423
28 0.126 0.117 0.116 0.189 0.232 0.221 108 0.750 0.936 1.005 0.711 0.899 1.155
29 0.116 0.155 0.089 0.204 0.269 0.169 109 0.448 0.693 0.515 0.303 0.438 0.417
30 0.117 0.147 0.097 0.158 0.186 0.103 110 0.190 0.180 0.224 0.249 0.311 0.362
31 0.255 0.377 0.111 0.242 0.398 0.114 111 0.115 0.116 0.126 0.155 0.181 0.174
32 0.074 0.150 0.085 0.140 0.204 0.136 112 0.209 0.238 0.267 0.243 0.290 0.253
33 0.146 0.202 0.017 0.192 0.305 0.178 113 0.133 0.167 0.148 0.201 0.372 0.302
34 0.177 0.246 0.257 0.242 0.293 0.338 114 0.177 0.204 0.231 0.223 0.282 0.354
35 0.167 0.212 0.200 0.203 0.240 0.279 115 0.234 0.306 0.201 0.272 0.352 0.317
36 0.086 0.100 0.123 0.144 0.147 0.165 116 0.199 0.214 0.213 0.236 0.273 0.349
37 0.990 1.212 1.066 0.310 0.351 0.371 117 0.422 0.560 0.482 0.314 0.436 0.470
38 0.099 0.108 0.073 0.190 0.249 0.223 118 0.116 0.165 0.149 0.175 0.271 0.235
39 0.224 0.298 0.213 0.258 0.294 0.265 119 0.172 0.208 0.202 0.226 0.336 0.289
40 0.100 0.184 0.087 0.118 0.212 0.107 120 0.157 0.168 0.143 0.219 0.211 0.228
41 0.159 0.250 0.236 0.334 0.344 0.427 121 0.135 0.311 0.189 0.140 0.332 0.196
42 0.139 0.148 0.211 0.193 0.264 0.316 122 0.160 0.233 0.274 0.259 0.387 0.341
43 0.069 0.063 0.096 0.110 0.121 0.151 123 0.079 0.091 0.113 0.136 0.209 0.193
44 0.074 0.085 0.094 0.121 0.140 0.144 124 0.092 0.125 0.133 0.182 0.258 0.237
45 0.282 0.319 0.304 0.392 0.432 0.516 125 0.217 0.250 0.252 0.286 0.374 0.330
46 0.135 0.195 0.186 0.291 0.438 0.475 126 0.068 0.070 0.077 0.133 0.183 0.161
47 0.167 0.240 0.201 0.278 0.402 0.342 127 0.099 0.092 0.111 0.170 0.223 0.138
48 0.140 0.278 0.151 0.219 0.366 0.285 128 0.197 0.138 0.238 0.298 0.284 0.282
49 0.132 0.183 0.145 0.184 0.251 0.194 129 0.166 0.134 0.079 0.202 0.173 0.183
50 0.156 0.169 0.215 0.149 0.179 0.222 130 0.114 0.081 0.161 0.188 0.219 0.273
51 0.073 0.080 0.099 0.124 0.171 0.149 131 0.137 0.129 0.189 0.207 0.225 0.294
52 0.080 0.120 0.124 0.162 0.239 0.179 132 0.094 0.086 0.106 0.133 0.159 0.178
53 0.135 0.121 0.216 0.164 0.286 0.288 133 0.264 0.180 0.302 0.321 0.345 0.434
54 0.102 0.118 0.126 0.146 0.200 0.174 134 0.175 0.148 0.156 0.216 0.253 0.257
55 0.265 0.295 0.260 0.251 0.289 0.275 135 0.171 0.170 0.246 0.198 0.243 0.315
56 0.115 0.233 0.228 0.208 0.293 0.190 136 0.183 0.200 0.166 0.212 0.294 0.269
57 0.124 0.172 0.172 0.213 0.227 0.193 137 0.274 0.281 0.187 0.277 0.378 0.292
58 0.080 0.097 0.140 0.155 0.201 0.215 138 0.323 0.341 0.437 0.286 0.247 0.364
59 0.186 0.217 0.247 0.286 0.457 0.363 139 0.195 0.205 0.181 0.196 0.242 0.264
60 0.058 0.079 0.093 0.094 0.140 0.086 140 0.198 0.171 0.244 0.179 0.185 0.238
61 0.144 0.192 0.159 0.171 0.222 0.212 141 0.165 0.157 0.175 0.226 0.246 0.344
62 0.111 0.140 0.148 0.213 0.304 0.267 142 0.099 0.128 0.093 0.125 0.168 0.170
63 0.173 0.194 0.195 0.163 0.257 0.176 143 0.187 0.230 0.260 0.197 0.209 0.258
64 0.120 0.125 0.110 0.140 0.204 0.099 144 0.345 0.434 0.401 0.456 0.571 0.556
65 0.202 0.184 0.292 0.294 0.370 0.553 145 0.606 0.275 0.304 0.373 0.426 0.483
66 0.111 0.103 0.127 0.171 0.194 0.221 146 0.191 0.219 0.235 0.230 0.285 0.368
67 0.274 0.238 0.336 0.254 0.284 0.313 147 0.173 0.238 0.268 0.224 0.273 0.337
68 0.124 0.112 0.141 0.135 0.167 0.179 148 0.162 0.204 0.316 0.256 0.303 0.384
69 0.423 0.579 0.660 0.414 0.723 0.936 149 0.095 0.070 0.063 0.085 0.133 0.141
70 0.133 0.153 0.137 0.219 0.298 0.258 150 0.139 0.116 0.122 0.131 0.223 0.178
71 0.479 0.498 0.449 0.374 0.491 0.427 151 0.180 0.225 0.288 0.196 0.335 0.341
72 0.143 0.298 0.144 0.187 0.409 0.296 152 0.210 0.258 0.265 0.227 0.286 0.301
73 0.148 0.186 0.123 0.210 0.253 0.257 153 0.276 0.292 0.342 0.271 0.291 0.260
74 0.106 0.119 0.153 0.143 0.163 0.206 154 0.156 0.262 0.387 0.271 0.277 0.310
75 0.152 0.161 0.153 0.228 0.298 0.288 155 0.224 0.266 0.301 0.277 0.318 0.436
76 0.501 0.635 0.571 0.231 0.292 0.370 156 0.252 0.296 0.352 0.273 0.398 0.466
77 0.142 0.184 0.206 0.194 0.223 0.302 157 0.114 0.129 0.119 0.117 0.155 0.226
78 0.152 0.175 0.155 0.197 0.228 0.206 158 0.115 0.146 0.144 0.118 0.164 0.202
79 0.109 0.136 0.139 0.198 0.237 0.245 159 0.290 0.323 0.341 0.308 0.377 0.449
80 0.122 0.222 0.116 0.169 0.325 0.230 160 0.274 0.413 0.380 0.254 0.479 0.325
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• The multi-tier approach for classification of immunoassays is evaluated
• The methods are illustrated on a real dataset
• The methods are compared via simulation
• We find that the overall performance of the multi-stage process is dominated by the method 
used for confirmation
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